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Abstract
Background: Small cell lung cancer (SCLC) is normally diagnosed with hema-
toxylin and eosin stains, although some cases require immunohistochemistry
(IHC). P40 is highly sensitive and specific for squamous cell carcinoma and is
thus considered the best marker for this cancer. However, the status of p40
expression in SCLC is not well known. The aim of this study was to analyze p40
expression in resected SCLC using IHC.
Methods: Forty-four surgically resected SCLC cases were enrolled. Clinical data
were obtained from the patients’ medical records. Pathologists blinded to the
patients’ clinical data reviewed the SCLC slides. IHC was performed on a repre-
sentative slide of each case.
Results: Although p40 was not diffusely expressed in any of the SCLC cases,
p40-positive cells were observed in the tumors in 15 cases (34.1%). Ten of these
exhibited p40 in < 1% of tumor cells. In the remaining five cases, 1–5% of tumor
cells expressed p40, and in three of these, the cells expressing p40 also expressed
TTF-1 and neuroendocrine markers. There was no statistically significant rela-
tionship between p40 positivity and any other clinicopathological characteristics.
Conclusions: Some resected SCLCs express p40 focally. This result suggests that
the presence of positive p40 cells does not exclude a diagnosis of SCLC. Thus,
small biopsy or cytology specimens with p40-positive cells must be diagnosed
carefully.
Introduction
Small cell lung cancer (SCLC) accounts for approximately
14% of all newly diagnosed lung cancer cases.1 SCLCs are
normally diagnosed with hematoxylin and eosin
(HE) staining using small biopsy and cytology specimens.2
However, some cases require immunohistochemistry
(IHC) to differentiate them from lymphomas, low-grade
neuroendocrine tumors, or basaloid squamous cell carcino-
mas (SCCs).
Several SCC markers can be detected using IHC: CK5/6,
DSM3, p40, and p63. P40, an isoform of p63 (deltaNp63),
is a highly sensitive and specific marker of SCC. In
previous reports, both the sensitivity and specificity of p40
for diagnosing pulmonary SCC have been almost 100%.3–5
Thus, p40 is known as the best marker of this cancer.2
However, the status of p40 expression in SCLC is not well
known.6–8 The aim of this study was to analyze p40 expres-
sion in resected SCLC using IHC.
Methods
Patient cohort
We prepared two patient datasets for this study. First,
between January 2005 and December 2017, 2486 patients
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with primary lung carcinoma underwent pulmonary re-
section at Kyoto University Hospital. Thirty-eight of these
cases (1.5%) were SCLC. One patient administered chemo-
therapy before surgery and four patients whose clinical
data were unavailable were excluded. The remaining
33 cases were enrolled. Second, between January 2009 and
December 2017, 625 patients with primary lung carcinoma
underwent pulmonary resection at the National Hospital
Organization, Kyoto Medical Center. Eleven of these
625 cases (1.8%) were SCLC. All 11 cases were enrolled in
this study. Clinical data, including gender, age, smoking
status, and serum tumor marker levels of progastrin releas-
ing peptide (pro-GRP) and neuron-specific enolase (NSE),
were obtained from the medical records of both patient
datasets.
Patients were informed about the possibility of their tis-
sue samples being used for academic research, and were
advised that they could opt out of this research. The insti-
tutional ethics committees of Kyoto University Hospital
(R1324-1) and the National Hospital Organization Kyoto
Medical Center (18–041) granted approval of this retro-
spective study.
Histologic evaluation
All resected specimens were fixed in formalin, sectioned,
and stained with HE in the conventional manner. Elastic
stains (Elastica van Gieson, Elastica-Masson, or Victoria
Blue, Muto Pure Chemicals, Tokyo, Japan) were also per-
formed to detect invasion of the pleura or vessels. Two
pathologists blinded to the patient’s clinical data reviewed
the SCLC slides. All cases were classified according to 2015
World Health Organization criteria.1 SCLC was classified
based on specific histological and cytological features on
HE staining; the decision was not altered on the basis of
IHC findings. In addition, tumor staging was performed
according to the 8th edition of the International Union
Against Cancer Tumor Node Metastasis Classification.9
Lymphatic, vascular, and pleural invasion, and/or spread
through air spaces, were assessed.
Immunohistochemistry
IHC was performed on a representative slide of each case.
We used a specific antibody to p40 (clone BC28; Roche,
Basel, Switzerland). The association between p40 and pro-
tein expression was evaluated using the following anti-
bodies: TTF-1 (clone 8G7G3/1), CgA (polyclonal A0430)
and Ki-67 (clone MIB-1, Dako, Glostrup, Denmark); SYN
(clone MRQ-40) and CK5 (clone SP27, Roche); CD56
(clone 1B6, Leica Microsystems, Wetzlar, Germany); and
DSC3 (clone Dsc3-U114, PROGEN Biotechnik, Heidelberg,
Germany). IHC was performed with an automatic
immunostainer (Benchmark, Ventana Medical Systems,
Tucson, AZ, USA) according to the manufacturer’s
instructions. For CgA, SYN, and CD56, positive staining
was defined as ≥ 10% positive tumor cells according to
2015 World Health Organization classification criteria for
large cell neuroendocrine carcinoma.1 For TTF-1 and
DSM3, positive staining was also defined as ≥ 10% positive
tumor cells. Co-expression of p40 with other antigens was
determined by comparing two slides.
Statistical analysis
Data were analyzed using JMP Pro version 12.2.0. Com-
parisons between two groups were performed using Fish-
er’s exact test to analyze categorical variables. Statistical
significance was indicated at P < 0.05.
Table 1 Association between p40 expression and clinical characteristics
of small cell lung cancer
Expression of p40
Characteristics Positive (≥ 1%) Negative (< 1%) P
Total 5 39
Age
≥ 65 3 31 0.59
< 65 2 8
Gender
Male 2 29 0.32
Female 3 10
Smoking
Never 0 2 1.00
Ever 5 37
T Stage








N0 2 26 0.62
N1-3 3 8
M Stage
M0 5 38 1.00
M1 0 1
Stage
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Results
Of the 44 total cases studied, 30 were pure SCLC, four
were combined SCLC and SCC, nine were combined SCLC
and adenocarcinoma, and one was combined SCLC and
large cell neuroendocrine tumor. The clinicopathological
features of these 44 cases are listed in Tables 1 and 2.
Although p40 was not diffusely expressed in any of the
SCLC cases, p40-positive cells were observed in 15 cases
(34.1%): in 10 cases, < 1% of tumor cells were positive in a
whole slide; in three cases, 1–5% of tumor cells were posi-
tive in a whole slide; and in two cases, > 10% of tumor cells
were positive in a focal area (Fig 1a–d). The cytological fea-
tures of the p40-positive tumor cells did not differ from
those of surrounding p40-negative cells (Fig 1c,d); the
p40-positive tumor cells were morphologically diagnosed
as SCLC. Regarding p40 positivity of the corresponding
biopsy specimens, biopsy before resection was performed
in only seven cases. Among these seven cases, one biopsy
specimen contained tumor tissue and no p40-positive cells
were observed.
We examined five cases in which > 1% of the tumor
cells expressed p40 to determine whether p40-positive
tumor cells also expressed TTF-1, neuroendocrine makers,
or other SCC markers (Table 3). In a case of combined
SCLC and SCC (case 2), IHC evaluation was performed on
the SCLC area. In two of these cases (cases 1 and 3),
p40-positive tumor cells expressed TTF-1, SYN, CD56, and
CK5. In one case (case 5), p40-positive tumor cells
expressed TTF-1, SYN, and CK5. In the remaining two
cases (cases 2 and 4), p40-positive tumor cells did not
express TTF-1, neuroendocrine markers, or CK5.
Information about the serum pro-GRP level was avail-
able in 30 cases. The mean serum pro-GRP level was 78.2
pg./mL (range: 20.7–317 pg./mL) in cases with
p40-negative tumors and 78.8 pg./mL (range: 27.9–143 pg./
mL) in cases with p40-positive tumors. Information about
the serum NSE level was available in 32 cases. The mean
serum NSE level was 12.57 ng/mL (range: 4.10–26.97
ng/mL) in cases with p40-negative tumors and 15.63
ng/mL (range: 11.05–21.99 ng/mL) in cases with
p40-positive tumors.
There was no statistically significant relationship
between p40 positivity and any other clinicopathological
characteristics (Tables 1–2).
Discussion
P40 is regarded as the best marker of SCC; however, the
status of p40 expression in SCLC has not been well studied.
We showed that 34.1% of resected SCLCs express p40
Table 2 Association between p40 expression and histological charac-
teristics of SCLC
Expression of p40
Characteristics Positive (≥ 1%) Negative (< 1%) P
Histological subtype
SCLC 4 26 0.55
SCLC + SCC 1 3
SCLC + ADC 0 9
SCLC + LCNEC 0 1
Pleural invasion
Present 2 18 1.00
Absent 3 21
Vascular invasion
Present 4 24 0.64
Absent 1 15
Lymphatic invasion
Present 3 17 0.65
Absent 2 22
STAS
Present 4 29 1.00
Absent 1 10
ADC, adenocarcinoma; LCNEC, large cell neuroendocrine tumor; SCC,
squamous cell carcinoma; SCLC, small cell lung cancer; STAS, spread
though air spaces.
Figure 1 A representative case of p40-positive small cell lung cancer.
(a,c) Hematoxylin and eosin staining. Immunohistochemical images of
(b,d) p40, (e) SYN, and (f ) TTF-1. (b) Low power view shows foci
expressing p40. (c,d) High power views show that the morphology of
p40-expressing cells is the same as p40-negative cells. (e,f ) Co-
expression of SYN and TTF-1 is observed. Bars indicate 100 μm.
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focally. These results indicate that p40 positivity does not
always exclude a diagnosis of SCLC.
Few reports mention p40 expression status in SCLC and
most of these reported that p40 was not expressed in SCLC
tumor cells.6,7,10 Brown et al. used a dual-antibody cocktail
to assess p40/TTF-1, and positive nuclear red staining in >
1% of tumor cells was scored as positive for p40, showing
that all SCLC cases (n = 35) were identified by strong posi-
tive staining for TTF-1 and negative staining for p40.7 This
result might indicate no or ≥ 1% expression of p40 in their
series; however, we believe that it would have been difficult
to recognize p40 positive cells because they used a dual-
antibody cocktail. Thus their result does not conflict with
ours. Among 78 biopsies and 18 surgical specimens,
Miyauchi et al. found no SCLC samples positive for p40;
however, they may have ignored a small number of
p40-positive cells in SCLC because they did not report the
threshold.10 Butonor et al. also did not observe nuclear p40
immunoreactivity in 27 biopsy samples or seven resection/
autopsy specimens.6 In our study, the p40-positive area in
SCLC was very limited, thus we suggest that examination of
a resected specimen is essential to determine whether SCLC
expresses p40. The number of resected specimens in the
study by Butonor et al. was smaller than ours, thus, our
findings are more robust.
A study by Lilo et al. demonstrated that p40 was focally
and weakly positive in 12.5% (1/8) of SCLC cases using
fine needle aspiration material.8 This report supports our
assumption that SCLC can express p40 focally. Tumor cells
taken from a lung nodule with p40 expression may lead
pathologists to diagnose the tumor as SCC; however, our
study showed that p40 positivity does not always
exclude SCLC.
Interestingly, we found co-expression of p40 and TTF-1
in our sample. Tanaka et al. reported that co-expression of
p40 and TTF-1 was observed in a type of peripheral lung
epithelial stem cell.11 This finding may indicate that co-
expression of p40 and TTF-1 in SCLC implies stem cell-
like features rather than squamous cell differentiation.
There are some limitations to this study. First, our results
were obtained using a small number of cases because
patients with SCLC are usually treated with chemotherapy
and/or radiotherapy and were thus excluded. However, to
the best of our knowledge, our SCLC cohort contains the
largest number of resected specimens used to estimate p40
expression among reported SCLC cohorts. Second, we could
not perform immunofluorescence or double staining to con-
firm the co-expression of p40 and other antigens because
p40 was expressed focally. As an alternative, we compared
two slides (e.g. p40 and CgA) to determine the presence of
co-expression. Third, most cases enrolled in this study were
early stage SCLC, although most cases of SCLC are detected
in advanced stage.2 The frequency of p40 positivity in
advanced stage SCLC might be different from that in early
stage SCLC. However, we consider it impossible to evaluate
p40 status in advanced stage tumors.
In conclusion, we show that resected tissue from cases of
SCLC express p40 focally. This result suggests that positiv-
ity for p40 does not exclude SCLC. Thus, small biopsy or
cytology specimens with p40-positive cells must be diag-
nosed carefully.
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